Morningstar | Intercept Advances in NASH With Positive Top-Line Results in Liver Fibrosis; Shares Undervalued
Intercept reported positive top-line results from its phase 3 results of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH) on Feb. 19. The trial met one of its two primary endpoints (and therefore met its primary objective), with patients on OCA (25 mgs) showing fibrosis improvement with no worsening of disease after 18 months with high statistical significance. Further, patients on OCA (both 10 mg and 25 mg doses) showed a trend toward NASH resolution, but this did not reach statistical significance. These results support our long-term outlook for OCA in NASH, as we believe the 25 mg dose shows strong efficacy and has potential to be first to market, resulting in solid market share expectations in the medium term. However, we believe side effects leave room for competing drugs to take share in the long term.Consistent with prior studies, common side effects were dose-dependent pruritis (severe itching) and heightened LDL cholesterol. While 51% of OCA 25 mg patients exhibited pruritis (compared with 19% placebo), only 2% of OCA 25 mg patients experienced serious cardiovascular events (compared with 2% placebo). We do not believe OCA's LDL-raising effects alone would bar the drug from prescriber adoption or approval. The company expects to file in the second half of 2019, and we expect more detailed interim data at a liver conference in April.
Overall, we think these results are in line with our expectations, so we don't anticipate any material changes to our model. We continue to believe that the NASH opportunity is not fully baked into shares, and we reiterate our $150 fair value estimate for Intercept.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The company's marketed product, Ocaliva? (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, the company is developing OCA for multiple indications, including nonalcoholic steatohepatitis.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.